GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
In patients with acute myocardial infarction who are managed in the prehospital setting, and
who will treated with primary angioplasty, we evaluate the benefit of an early administration
of tirofiban, a powerful GPIIbIIIa inhibitors. Patients are randomised to early
administration in the ambulance or administration in the cathlab. The primary endpoint is
TIMI 2-3 flow in the first coronary opacification of the culprit artery.